Vaccine Study for Surgically Resected Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

December 31, 2014

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

HyperAcute(R)-Pancreatic Cancer Vaccine

100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months

Trial Locations (18)

19107

Thomas Jefferson University, Philadelphia

33136

University of Miami, Miami

44106

University Hospitals Case Western, Cleveland

46202

Indiana University, Indianapolis

55455

University of Minnesota Cancer Center, Minneapolis

60201

Evanston Northwestern Healthcare, Evanston

60611

Northwestern University, Chicago

77030

Baylor College of Medicine, Houston

78229

University of Texas Health Science Center, San Antonio

80045

University of Colorado, Aurora

85259

Mayo Clinic - Scottsdale, Scottsdale

87131

University of New Mexico, Albuquerque

90033

University of Southern California, Los Angeles

92868

University of California - Irvine, Orange

94115

California Pacific Medical Center, San Francisco

01805

Lahey Clinic, Burlington

02903

Rhode Island Hospital, Providence

02908

Roger Williams Medical Center, Providence

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT00569387 - Vaccine Study for Surgically Resected Pancreatic Cancer | Biotech Hunter | Biotech Hunter